Videos | Page 3

Why-Should-Hydrocodone-Combination-Products-Be-Categorized-as-CII-Drugs
Mary Lynn McPherson, PharmD, explains why hydrocodone combination products should no longer be categorized as Schedule III drugs.
Codeine-and-Rescheduling-Hydrocodone-Combination-Products
Jeff Fudin, PharmD, FCCP, argues that categorizing hydrocodone combination products as Schedule II could lead to increased prescription of codeine, a much “sloppier” drug that could create problems for patients.
Rescheduling-Hydrocodone-Combination-Products-Will-Lead-to-More-Responsible-Use
Mary Lynn McPherson, PharmD, argues that rescheduling hydrocodone combination products will lead to more responsible prescribing of the drugs and monitoring of their use.
Rescheduling-Hydrocodone-Combination-Products-Lessons-from-New-York-State
Jeff Fudin, PharmD, FCCP, discusses the effect of rescheduling hydrocodone combination products as CII in New York State on prescription of other opioids, including oxycodone.
How-Rescheduling-Hydrocodone-Combination-Products-Will-Reduce-Abuse
Mary Lynn McPherson, PharmD, explains how rescheduling hydrocodone combination products as Schedule II drugs will help reduce levels of abuse.
Abuse-Liability-of-Hydrocodone-Combination-Products
Jeff Fudin, PharmD, FCCP, argues that studies comparing the abuse liability of hydrocodone combination products with that of other opioids have produced conflicting results.
Rationale-for-Categorizing-Hydrocodone-Combination-Products-as-Schedule-III
Mary Lynn McPherson, PharmD, discusses why hydrocodone combination products were categorized as Schedule III in the first place.
Will-Rescheduling-Hydrocodone-Combination-Products-Actually-Reduce-Abuse
Jeff Fudin, PharmD, FCCP, argues that categorizing hydrocodone combination products as Schedule II drugs is unlikely to reduce abuse of the medications.
Effect-of-Beta-Blockers-on-Mortality-after-Myocardial-Infarction-in-Adults-with-COPD
Researchers discuss their study of COPD patients who have experienced a first myocardial infarction and the impact of beta-blocker therapy on mortality.
Marine-Compound-Discovery-Shows-Promise-of-Improved-Drug-Treatment-for-COPD-Patients
University of Florida pharmacy researchers have isolated a compound from blue-green algae that may inhibit the progression of pulmonary disease.
$AD300x250BB$
Latest Issues
$auto_registration$